New cell therapy aims to tame tough autoimmune diseases
NCT ID NCT07236801
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new cell therapy called YTS109 in 18 adults with severe autoimmune diseases like lupus and Sjogren's syndrome that have not responded to standard treatments. Participants receive a single infusion of the cells, and researchers monitor safety and how well the therapy controls the disease. The goal is to see if this approach can reduce symptoms and improve quality of life.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Affiliated Hospital of Xuzhou Medical University
RECRUITINGXuzhou, Jiangsu, China
-
The Affiliated Hospital of Xuzhou Medical University
RECRUITINGXuzhou, Jiangsu, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A simple blood test may reveal kidney damage in lupus — no biopsy needed?
- Can a Three-Drug combo quiet lupus kidney flares?
- Can a new antibody tame lupus flares?
- Blood platelet trends may reveal hidden risk in autoimmune disease
- Can a single infusion tame tough lupus?
- Immune clues in the blood may foretell heart trouble